Bone mineral density in women with polycystic ovary syndrome

Molecular Diagnosis and Therapy

Volumn 37, Issue 12, 2014, Pages 1219-1224

  Katulski, K ^a   Slawek, S ^a   Czyzyk, A ^a   Podfigurna Stopa, A ^a   Paczkowska, K ^a   Ignaszak, N ^a   Podkowa, N ^a   Meczekalski, B ^a  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

Bone mineral density (BMD); HOMA IR; Polycystic ovary syndrome (PCOS); Z Score hyperandrogenism

Indexed keywords

ESTRADIOL; FOLLITROPIN; GONADOTROPIN; INSULIN; LUTEINIZING HORMONE; PRASTERONE SULFATE; PROLACTIN; TESTOSTERONE; GLUCOSE; THYROTROPIN; THYROXINE; BIOLOGICAL MARKER;

ADULT; ANOVULATION; ARTICLE; BODY MASS; BONE DENSITY; BONE GROWTH STIMULATOR; CONGENITAL ADRENAL HYPERPLASIA; CUSHING SYNDROME; DUAL ENERGY X RAY ABSORPTIOMETRY; ESTROGEN DEFICIENCY; FEMALE; FREE THYROXINE INDEX; HUMAN; HYPERANDROGENISM; HYPERPROLACTINEMIA; INSULIN RESISTANCE; LUMBAR SPINE; MAJOR CLINICAL STUDY; MENSTRUAL IRREGULARITY; METABOLIC PARAMETERS; OBESITY; OVARY POLYCYSTIC DISEASE; QUALITY CONTROL PROCEDURES; SECONDARY AMENORRHEA; SPINE RADIOGRAPHY; VAGINA BLEEDING; ADOLESCENT; CONTROLLED STUDY; ECHOGRAPHY; ESTRADIOL BLOOD LEVEL; FOLLITROPIN BLOOD LEVEL; GLUCOSE BLOOD LEVEL; GONADOTROPIN BLOOD LEVEL; HIRSUTISM; INSULIN BLOOD LEVEL; LUTEINIZING HORMONE BLOOD LEVEL; OSSIFICATION; PROLACTIN BLOOD LEVEL; TESTOSTERONE BLOOD LEVEL; THYROTROPIN BLOOD LEVEL; BLOOD; COMPLICATION; LUMBAR VERTEBRA; METABOLISM; PATHOLOGY; PHYSIOLOGY; POLYCYSTIC OVARY SYNDROME; YOUNG ADULT;

ADOLESCENT; ADULT; BIOMARKERS; BONE DENSITY; FEMALE; FOLLICLE STIMULATING HORMONE; HUMANS; INSULIN; LUMBAR VERTEBRAE; LUTEINIZING HORMONE; POLYCYSTIC OVARY SYNDROME; TESTOSTERONE; YOUNG ADULT;

EID: 84939574213     PISSN: 11771062     EISSN: 11792000     Source Type: Journal    
DOI: 10.1007/s40618-014-0175-5     Document Type: Article

References (33)

1. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group (2004) Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 81(1):19–25
2. Katulski K, Czyżyk A, Męczekalski B (2012) The controversies in the diagnosis of polycystic ovary syndrome. Pol Merk Lek 193:32–37
3. Bonjour J, Theintz G, Law F, Slosman D, Rizzoli R (1994) Peak bone mass. Osteo Int 4:7–13
4. Carmina E, Guastella E, Longo RA, Rini GB, Lobo RA (2009) Correlates of increased lean muscle mass in women with polycystic ovary syndrome. Eur J Endocrinol 161:583–589
5. Warenik-Szymankiewicz A, Męczekalski B (2007) Wpływ estrogenów na metabolizm tkanki kostnej w warunkach fizjologii i patologii. Stand Med 4:143–145
6. Yüksel O, Dokmetas HS, Topcu S, Erselcan T, Sencan M (2001) Relationship between bone mineral density and insulin resistance in polycystic ovary syndrome.J. Bone Miner Metab 19:257–262
7. Di Carlo C, Shoham Z, MacDougall J, Patel A, Hall ML, Jacobs HS (1992) Polycystic ovaries as a relative protective factor for bone mineral loss in young women with amenorrhea. Fertil Steril 57:314–319
8. Nestler J, Powers I, Matt D (1991) A direct effect of hyperinsulinemia on serum sex hormone binding globulin levels in obese women with the polycystic ovary syndrome. J Clin Endocrinol Metab 72:83–89
9. Barrett-Connor E, Kritz-Silverstein D (1996) Does hyperinsulinemia preserve bone? Diab Are 19:1388–1392
10. Zborowski JV, Cauley JA, Talbott EO, Guzick DS, Winters SJ (2000) Bone mineral density, androgens and the polycystic ovary: the complex and controversial issue of androgenic influence in female bone. J Clin Endocrinol Metab 85:3496–3506
11. Prior JC, Vigna YM, Schechter MT, Burgess AE (1990) Spinal bone loss and ovulatory disturbances. N Engl J Med 323:1221–1227
12. Warenik-Szymankiewicz A, Męczekalski B (2005) Pierwotny i wtórny hipoestrogenizm a ryzyko osteoporozy u młodych kobiet. Terapia 2:7–9
13. Dunaif A (1997) Insulin resistance and the polycystic ovary syndrome: mechanisms and implications for pathogenesis. Endocrinol Rev 18:774–800
14. Meenakumari KJ, Agarwal S, Krishna A, Pandey LK (2004) Effects of metformin treatment on luteal phase progesterone concentration in polycystic ovary syndrome. Braz J Med Bio. Res 37:1637–1644
15. Morales AJ, Laughlin GA, Butzow T, Maheshwari H, Bauman G, Yen SS (1996) Insulin, somatotropic, and luteinizing hormone axes in lean and obese women with polycystic ovary syndrome: common and distinct features. J Clin Endocrinol Metab 81:2854–2864
16. Kirchengast S, Huber J (2001) Body composition characteristics and body fat distribution in women with polycystic ovary syndrome. Hum Reprod 16:1255–1260
17. Rajkhowa M, Clayton RN (1995) Polycystic ovary syndrome. Current. Obstet Gynecol 5:191–200
18. Adami S, Zamberlan N, Castello R, Tosi F, Gatti D, Moghetti P (1998) Effect of hyperandrogenism and menstrual cycle abnormalities on bone mass and bone turnover in young women. Clin Endocrinol 48:169–173
19. Good C, Tulchinsky M, Mauger D, Derners LM, Legro RS (1992) Bone mineral density and body composition in lean women with polycystic ovary syndrome. Fertil Steril 72:21–25
20. Dixon JE, Rodin A, Murby B, Chapman MG, Fogelman I (1990) Bone mass in hirsute women with androgen excess. Clin Endocrinol 30:271–277
21. Dagogo-Jack S, al-Ali N, Qurttom M (1997) Augmentation of bone mineral density in hirsute women. J Clin Endocrinol Metab 82:2821–2825
22. Noyan V, Yucel A, Sagsoz N (2004) The association of bone mineral density with insulin resistance in patients with polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol 115(2):200–205
23. Lobo RA, Kelzky OA, Compeau JD, Di Zerga GS (1983) Elevated bioactive luteinizing hormone in women with polycystic ovary syndrome. Fertil Steril 39:674–678
24. Horst-Sikorska W, Ignaszak-Szczepaniak M (2011) The role of anorexia nervosa in secondary osteoporosis development with the risk for low energy fractures. Endokrynol Pol 62:45–47
25. Pasquali R, Gambineri A (2013) Glucose intolerance states in women with the polycystic ovary syndrome. J Endocrinol Invest 36(8):648–653
26. Conway GS, Jacobs HS, Holly JM, Wass JA (1990) Effect of luteinizing hormone, insulin, insulin like growth factor, and insulin like growth factor small protein in polycystic ovary syndrome. Clin Endocrinol 33:593–603
27. Glintborg D, Anderson M, Hagen C, Heickendorff G, Hermann AP (2008) Association of pioglitazone treatment with decreased bone mineral density in obese premenopausal patients with polycystic ovary syndrome: a randomized, placebo-controlled trial. J Clin Endocrinol Metab 93:1696–1701
28. Kassanos D, Trakakis E, Baltas CS, Papakonstantinou O, Simeonidis G, Salamalekis G, Grammatikakis I, Basios G, Labos G, Skarantavos G, Balanika A (2010) Augmentation of cortical bone mineral density in women with polycystic ovary syndrome: a peripheral quantitative computed tomography (pQCT) study. Hum Reprod 25:2107–2114
29. Kley KH, Deselaer S, Peerenboom H, Krueskemper H (1980) Enhanced conversion of androstenedione to estrogens in obese males. J Clin Endocrinol Metab 51:1128–1132
30. Warren MP, Perloth E (2001) The effects of intense exercise on the female reproductive system. J Endocrinol 170:3–11
31. Douchi T, Oki T, Yamasaki H, Kuwahata R, Nakae M, Nagata Y (2001) Relationship of androgens to muscle size and bone mineral density in women with polycystic ovary syndrome. Obstet Gynecol 98:445–449
32. Vanderschueren D, Vandenput L, Boonen S, Lindbeg G, Bouillon R, Ohlsson C (2004) Androgens and bone. Endo Rev 25:389–425
33. Notelovitz M (2002) Androgen effects on bone and muscle. Fertil Steril 77(Suppl 4):34–41